belatacept   Click here for help

GtoPdb Ligand ID: 6892

Synonyms: BMS-224818 | LEA29Y | Nulojix®
Approved drug Immunopharmacology Ligand
belatacept is an approved drug (FDA (2011), EMA (2011))
Compound class: Peptide or derivative
Comment: A recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). CTLA-4 is essential for T-cell co-activation.
Belatecept differs from abatacept by only 2 amino acids.
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: belatacept

Classification Click here for help
Compound class Peptide or derivative
Ligand families/groups Immune checkpoint modulators
Approved drug? Yes (FDA (2011), EMA (2011))
International Nonproprietary Names Click here for help
INN number INN
8627 belatacept
Synonyms Click here for help
BMS-224818 | LEA29Y | Nulojix®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 247
Other databases
ChEMBL Ligand CHEMBL1742990 (Hs)
DrugBank Ligand DB06681
GtoPdb PubChem SID 178103474
PubChem SID 135283321
Search PubMed clinical trials belatacept
Search PubMed titles belatacept
Search PubMed titles/abstracts belatacept
Wikipedia Belatacept